Compliance Radar
Who was sanctioned, and for what?
Fines, court rulings and incidents from Europe and North America: 756 cases from 32 jurisdictions, each with an official source and checked against that source before publication. Filter by country, area of law and sector. Click a chart to drill down one level.
Click a bar to drill down one level.
Where?
by regionAll jurisdictions
What for?
by topicWho?
by companyWhen?
per quarter, by date of decision| Period | Cases | Total |
|---|---|---|
| Q3 2023 | 0 | — |
| Q4 2023 | 0 | — |
| Q1 2024 | 0 | — |
| Q2 2024 | 0 | — |
| Q3 2024 | 0 | — |
| Q4 2024 | 0 | — |
| Q1 2025 | 1 | €800,000 |
| Q2 2025 | 0 | — |
| Q3 2025 | 0 | — |
| Q4 2025 | 0 | — |
| Q1 2026 | 0 | — |
| Q2 2026 | 1 | €288,298 |
| Q3 2026 | 0 | — |
2 cases
20 Jan 2025 Pharnext SAPharnext: FDA setbacks disclosed late and glossed over €800,000
The biotech company did not disclose as soon as possible the FDA's request for an additional study on PXT-3003 and the subsequent rejection of an SPA application, and disseminated misleading communications to shareholders. Sanctions: Pharnext 500,000 EUR, former CEO Daniel Cohen 200,000 EUR, former CEO David Horn Solomon 100,000 EUR.
Negative feedback from regulatory authorities is regularly inside information and must not be given a positive spin in letters to shareholders.
- Authority / court
- Autorité des marchés financiers (AMF), Commission des sanctions
- Area of law
- Capital markets and financial supervision · Disclosure and reporting obligations
- Legal basis
- Art. 17 MAR; Art. 12 Abs. 1 lit. c und Art. 15 MAR
- Action
- Fine
- Status of proceedings
- under appeal
- Sector
- Chemicals and pharmaceuticals
- Liability of senior managers
- Daniel Cohen (co-founder, directeur général until April 2020): 200,000 EUR; David Horn Solomon (directeur général from April 2020): 100,000 EUR
- Décision SAN-2025-01 Decision of an authority
- Décision n° 1 du 20 janvier 2025 (PDF) Decision of an authority
Checked against the official source on 25 Sep 2026 · Direct link
Report an error
6 Apr 2026 Caroline J. Campbell (Beschäftigte der ImmunityBio, Inc.)ImmunityBio employee sells shares ahead of news of FDA delay €288,298
In May 2023, an employee of the biotech company sold 48,495 shares with knowledge of the non-public information that the FDA would delay approval of the medicine Anktiva; after the announcement, the share price fell by around 55 %. Under the settlement, she is paying 157,066.28 USD in disgorgement, 18,130.97 USD in interest and a civil penalty of 157,066.28 USD.
Trading bans and blackout periods must be known to all employees with access to approval or trial data, not just to the management board.
Insider trading ban for employees, handling of approval information
- Authority / court
- U.S. Securities and Exchange Commission (SEC)
- Area of law
- Capital markets and financial supervision · Market abuse and insider dealing
- Legal basis
- Section 10(b) Securities Exchange Act 1934, Rule 10b-5
- Action
- Fine
- Status of proceedings
- final
- Sector
- Chemicals and pharmaceuticals
Original amount 332,263.53 USD, converted at the ECB reference rate of 2 Apr 2026.
- SEC Files Settled Insider Trading Charges Against California Biotech Employee Decision of an authority
Checked against the official source on 25 Sep 2026 · Direct link